For patients in the secondary AML subgroup, there was no statistical difference in OS according to mutational status of RUNX1 and TET2 genes in the glasdegib + LDAC arm; however, there was a negative correlation with mutations in DNMT3A (p = 0.0056) compared with patients with wild-type DNMT3A. DNMT3A mutations were associated with a short OS in both the glasdegib + LDAC and LDAC alone arms (3.1 and 1.9 months, respectively). This evidence concerns the gene RUNX1 and acute myeloid leukemia.